1. Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis

   • Yee-Ming Melody Cheung
   • Wei Wang
   • Ole-Petter Riksfjord Hamnvik

   Review Article 13 January 2022 Pages: 1795 - 1812

   

2. Pediatric glioblastoma: mechanisms of immune evasion and potential therapeutic opportunities

   • Rosy Njonkou
   • Christopher M. Jackson
   • David S. Hersh

   Review Article 12 January 2022 Pages: 1813 - 1822

   

3. The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents

   • Carlos Zamora Atenza
   • Geòrgia Anguera
   • Margarita Majem

   Original Article 05 January 2022 Pages: 1823 - 1835

   

4. Combination immunotherapy including OncoVEX^mGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma

   • Robyn D. Gartrell
   • Zoë Blake
   • Yvonne M. Saenger

   Original Article 09 January 2022 Pages: 1837 - 1849

   

5. Blocking GARP-mediated activation of TGF-β1 did not alter innate or adaptive immune responses to bacterial infection or protein immunization in mice

   • Mélanie Gaignage
   • Xuhao Zhang
   • Sophie Lucas

   Original Article Open access 01 January 2022 Pages: 1851 - 1862

   

6. Functional virus-specific memory T cells survey glioblastoma

   • Jianfang Ning
   • Noah V. Gavil
   • Pamela C. Rosato

   Original Article 10 January 2022 Pages: 1863 - 1875

   

7. Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy

   • Ryuhei Okada
   • Takuya Kato
   • Hisataka Kobayashi

   Original Article 11 January 2022 Pages: 1877 - 1887

   

8. A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer

   • Bangyou Zuo
   • Xiaobo Yang
   • Haitao Zhao

   Original Article 13 January 2022 Pages: 1889 - 1896

   

9. Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial

   • Jifang Gong
   • Junning Cao
   • Lin Shen

   Original Article Open access 05 January 2022 Pages: 1897 - 1908

   

10. Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia

    • Fernanda Marconi Roversi
    • Maura Lima Pereira Bueno
    • Sara Teresinha Olalla Saad

    Original Article 18 January 2022 Pages: 1909 - 1921

    

11. Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma

    • Wenhao Xu
    • Chunguang Ma
    • Dingwei Ye

    Original Article 19 January 2022 Pages: 1923 - 1935

    

12. Alterations of circulating lymphocyte subsets in patients with colorectal carcinoma

    • Johanna Waidhauser
    • Pia Nerlinger
    • Andreas Rank

    Original Article Open access 20 December 2021 Pages: 1937 - 1947

    

13. Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence

    • Anna Małgorzata Czarnecka
    • Paweł Sobczuk
    • Piotr Rutkowski

    Original Article 25 January 2022 Pages: 1949 - 1958

    

14. Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells

    • Fei Liao
    • Jing Zhang
    • Qiao Li

    Original Article 31 January 2022 Pages: 1959 - 1973

    

15. Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16⁺ cancer

    • Nadja Salomon
    • Abderaouf Selmi
    • Fulvia Vascotto

    Original Article Open access 31 December 2021 Pages: 1975 - 1988

    

16. Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cells

    • Emily Cluff
    • Carina C. Magdaleno
    • Narendiran Rajasekaran

    Original Article Open access 09 January 2022 Pages: 1989 - 2005

    

17. Oral administration of a whole glucan particle (WGP)-based therapeutic cancer vaccine targeting macrophages inhibits tumor growth

    • Liuyang He
    • Yu Bai
    • Cui Tang

    Original Article 04 January 2022 Pages: 2007 - 2028

    

18. Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden

    • Julia Femel
    • Luuk van Hooren
    • Anna-Karin Olsson

    Original Article Open access 11 January 2022 Pages: 2029 - 2040

    

19. A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma

    • Eiji Kiyohara
    • Atsushi Tanemura
    • Yasufumi Kaneda

    Clinical Trial Report Open access 05 January 2022 Pages: 2041 - 2049

    

20. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment

    • Sophia B. Strobel
    • Devayani Machiraju
    • Jessica C. Hassel

    Research Report Open access 23 December 2021 Pages: 2051 - 2056